An international team of researchers, led by the University of Glasgow, hopes to find new ways to target opioid addiction ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, ...

Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...

President Donald Trump's plan to impose tariffs on goods from Mexico, Canada and China is partly aimed at combating the ...

Last week’s settlement that would see Purdue Pharma and its owners, the Sackler family, pay $7.4 billion to resolve lawsuits filed by state and local governments across the country is ...

1 Department of Anesthesiology and Pediatric Clinical Pharmacology Laboratory ... chronic pain or had received opioids within the previous 24 h; 6) patients or guardians refusing participation in the ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain ...

The Federal Drug Administration’s (FDA) approval on Friday of Journavx (suzetrigine) as a non-opioid treatment for moderate to severe acute pain is a significant milestone in pain management. This app ...

The number of deaths caused by fentanyl continues to drop in Florida. Last year, the Florida Medical Examiners released its ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...